Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

254.66

+9.78 (3.99%)

as of Jun 26, 2026, 8:00:00 pm Market Open.

696 watching

Investor Insights

Jun 28, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has garnered a generally positive outlook from various experts, particularly highlighting its strong performance in pharmaceuticals and medical devices after a recent spin-off of its orthopedics division. The company's robust drug pipeline is considered one of the best in the industry, contributing to a resilient stock performance even amidst market volatility. While there is a legal overhang due to ongoing talcum powder lawsuits, experts suggest that this has diminished in significance. The company's valuation appears reasonable, and many experts encourage buying on weakness, reflecting confidence in future growth prospects. Overall, JNJ is seen as a solid investment, especially for those interested in dividend growth and long-term potential.

Consensus

Positive

Valuation

Fair Value

Similar

BUY

Likes their non-prescription healthcare products business. Good P/E multiple and good dividend.

BUY

If you like pharmaceuticals, consider moving into Johnson & Johnson (JNJ-N).

HOLD

Only partly a big pharmaceutical. Also into medical devices, consumer products, cosmetic products so it is more diversified.

BUY

(Market Call Minute.) Have been held back by the pharmaceutical side of the business but the medical devices and consumer products is good.

COMMENT

Has done a great job in anybody's portfolio. Very stable price while the market has gyrated. Has performed so well on a relative basis that there may not be a lot left.

PAST TOP PICK

(A Top Pick May 8/07. Up 7%.) Now that the Cdn$ is below par, he is comfortable with the US market. Nice dividend yield and a low PE.

BUY ON WEAKNESS

Has the medical side as well as the consumer side. Its medical device side is facing a bit of problem and its drugs are likely to face increased scrutiny if there is a Democratic administration. Attractive in the $55-$58 range.

BUY

Wonderful company. Great management. Very strong balance sheet. Gives a bit of exposure in the Pharma and medical supply businesses as well as the consumer business. A good core holding. 2.65% yield.

Wealthica Track your Stocks in your Watch List

DON'T BUY

In the near term, he would avoid this one. Expensive compared to other pharmaceutical companies. Has some major drugs coming off patents. Some big question marks regarding its stent business. If it comes off some more, it's a good long-term stock to own.

DON'T BUY

One of the better performing drug related stocks. Part pharmaceutical, part medical devices and part consumer products. Consumer product area has done well. Stent has not been doing well. Where doing well on the drug side but have a number of drugs coming off patent in the next few years. Expensive at 15-16X 2009 earnings for a company whose growth rate is slowing down. (See his top picks for a drug stock.)

BUY

Very high-quality company. There are some issues around their stent business, but long-term it doesn't get much better. Trades at historically low multiple of about 15X.

BUY

Owning this gives him the buffer between the non-patent products/devices to the pharmaceuticals. Very inexpensive.

BUY

A very sound financial company, growing its earnings at 8% to 10% per year. Trades at about 15X earnings. 2.5% dividend yield. Pristine AAA balance sheet. A very stable holding.

BUY

This would be a fine way of playing the healthcare area. It's a defensive company. Had a few issues with the stent market, but the rest of their operations are just great.

BUY

Not only is this a pharmaceutical company, which he likes, it is also a medical device company as well as consumer products. Very well run, good company. Cheap. Good pipeline.

Showing 511 to 525 of 626 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Kevin Simpson

Capital Wealth Planning

Bryn Talkington

Requisite Capital Management

Andrey Omelchak

LionGuard Capital Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)